Matisse Capital

Position in FULC — Fulcrum Therapeutics, Inc.

CIK 1668256 PORTLAND, OR

Position in FULC

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$304,107

+$151,875 QoQ

Shares Held

39,649

+194.6% QoQ

Ownership

0.060%

of shares outstanding

% of Portfolio

0.16%

of 13F equity value

Holder Rank

#82

of 168 holders

Holding Since

Sep 2024

7 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

Matisse Capital holds $7,147,288 across 4 Biotechnology names. FULC ranks #4 (4.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	26,077	$5,964,592
2	SPRY	ARS Pharmaceuticals, Inc.	67,229	$539,848
3	WVE	Wave Life Sciences Ltd.	46,723	$338,741
4	FULC	Fulcrum Therapeutics, Inc. This page	39,649	$304,107

7 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$304,107	39,649	+194.6%	Shares	Sole	2026-05-08
2025-12-31	$152,232	13,460	-27.8%	Shares	Sole	2026-01-29
2025-09-30	$171,396	18,630	-28.6%	Shares	Sole	2025-10-29
2025-06-30	$179,568	26,100	-73.0%	Shares	Sole	2025-07-23
2025-03-31	$278,544	96,717	-24.7%	Shares	Sole	2025-04-24
2024-12-31	$603,691	128,445	+20.4%	Shares	Sole	2025-01-24
2024-09-30	$380,979	106,717	—	Shares	Sole	2024-10-17
No filing history on record for this holder in this stock.